AWAK Technologies
Singapore
About AWAK Technologies
AWAK Technologies develop wearable dialysis machines, 1kg and battery-operated, for continuous dialysis. The company was certified by SGS for ISO 13485 Quality Management System in September 2008 with the scope of designing, manufacturing and distributing medical devices. The Automated Wearable Artificial Kidney (AWAK) is based on tidal peritoneal dialysis. The technology is based on research by Profs David Lee & Martin Roberts of UCLA and VA Systems. The engineering and development of AWAK is done in Singapore with the collaboration of Temasek Polytechnic. The company has completed the R&D and is now in the clinical trial stage, targeting both FDA and CE certifications. The AWAK Regular Cartridge, is currently in pilot production stage and expected to enter clinical trial by the end of 2012. This wearable artificial kidney operates continuously and functions like a normal kidney. Being small , light (less than 1 kg) and battery-operated, the patients will be able to go about having daily routines, with no restriction to lifestyles such as work, travel and leisure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $77.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2023)
- Website: awak.com
- Phone: [email protected]
Industries & Categories
Electronics, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/awak-technologies-41567 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.